ReviewCancers2022
Emerging Canonical and Non-Canonical Roles of Granzyme B in Health and Disease.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Super-resolution imaging reveals altered actin architecture at CAR-T cell immune synapses.The Journal of cell biology · 2026Article
- Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.Molecular diagnosis & therapy · 2026Review
- Nephrotoxicity of Immune Checkpoint Inhibitors in Mice with a Human Immune System.bioRxiv : the preprint server for biology · 2026Article
- Epidermal MHC-II-mediated NK cell recruitment triggers keratinocyte pyroptosis, facilitating pathogenesis of psoriasis.Experimental & molecular medicine · 2026Article
- Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Functional study of peripheral blood CD8 + T cells in Epstein-Barr virus-associated infectious mononucleosis.Italian journal of pediatrics · 2026Article
- Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer.Cell communication and signaling : CCS · 2026Review
- Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment.Scientific reports · 2025Article
- Circulating immune cells exhibit distinct traits linked to metastatic burden in breast cancer.Breast cancer research : BCR · 2025Article
- Comprehensive Analysis of Granzymes and Perforin Family Genes in Multiple Cancers.Biomedicines · 2025Article
- Key genes associated with brain metastasis in non-small cell lung cancer: novel insights from bioinformatics analysis.Frontiers in bioinformatics · 2025Article
- The pro-tumorigenic roles of granzyme B: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Isolation of Apigenin from Sungkai (F1000Research · 2025Article
- Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.BMJ oncology · 2025Article
- Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment.Frontiers in immunology · 2025Review
- Granzyme B and melittin in cancer immunotherapy: molecular mechanisms and therapeutic perspectives in head and neck cancers.Frontiers in immunology · 2025Review
- Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (NanoScience and technology of advanced materials · 2025Article
- A novel metric-based approach of scoring early host immune response from oro-nasopharyngeal swabs predicts COVID-19 outcome.Scientific reports · 2024Article
- Construction of a gene signature associated with anoikis to evaluate the prognosis and immune infiltration in patients with colorectal cancer.Translational cancer research · 2024Article
- Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma.Cancer letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Granzyme (Gzm) family has classically been recognized as a cytotoxic tool utilized by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells to illicit cell death to infected and cancerous cells. Their importance is established based on evidence showing that deficiencies in these cell death executors result in defective immune responses. Recent findings have shown the importance of Granzyme B (GzmB) in regulatory immune cells, which may contribute to tumor growth and immune evasion during cancer development. Other studies have shown that members of the Gzm family are important for biological processes such as extracellular matrix remodeling, angiogenesis and organized vascular degradation. With this growing body of evidence, it is becoming more important to understand the broader function of Gzm's rather than a specific executor of cell death, and we should be aware of the many alternative roles that Gzm's play in physiological and pathological conditions. Therefore, we review the classical as well as novel non-canonical functions of GzmB and discuss approaches to utilize these new findings to address current gaps in our understanding of the immune system and tissue development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.